Knowledge Base
Evidence-based reference articles covering every aspect of retatrutide — from its novel triple-agonist mechanism to clinical trial outcomes, safety data, and development milestones. Each article is sourced from peer-reviewed research and regularly updated as new data emerges.
Essential Reading
Development History of Retatrutide: From Discovery to Phase 3
A timeline of retatrutide's development from preclinical discovery at Eli Lilly through Phase 1, Phase 2, and into the Phase 3 TRIUMPH program, including key milestones and regulatory pathway decisions.
Weight Loss Outcomes with Retatrutide: Clinical Trial Results and Analysis
A detailed analysis of weight reduction results from retatrutide clinical trials, including dose-response relationships, body composition changes, and contextual comparisons with other metabolic therapies.
Safety Profile of Retatrutide: Comprehensive Overview from Clinical Data
A thorough review of retatrutide's safety profile based on Phase 1 and Phase 2 clinical trial data, covering gastrointestinal adverse events, laboratory findings, cardiovascular signals, hepatic effects, and outstanding safety questions.
Mechanism of Action: How Retatrutide's Triple Receptor Agonism Works
A deep dive into retatrutide's triple GIP/GLP-1/glucagon receptor agonism, explaining how each receptor pathway contributes to the molecule's metabolic effects and why synergistic triple agonism exceeds single- or dual-target approaches.
All Articles
Is Retatrutide Approved? Current FDA Status and Availability (March 2026)
Definitive answer: retatrutide is NOT approved by the FDA or any regulatory authority as of March 2026. Learn about the Phase 3 TRIUMPH program status, TRIUMPH-4 results (-28.7% weight loss), expected approval timeline of 2027-2028, how to access through clinical trials, and warnings about illegitimate sources.
Retatrutide Side Effects: Complete Guide to Clinical Trial Safety Data
Detailed analysis of retatrutide side effects from Phase 2 and Phase 3 clinical trials, including gastrointestinal adverse events by dose level (4mg, 8mg, 12mg), comparison tables vs placebo, discontinuation rates, the TRIUMPH-4 dysesthesia signal, dose-escalation mitigation, and safety comparisons to other GLP-1 drugs.
Retatrutide Receptor Activity: GLP-1, GIP, and Glucagon Pathways
An in-depth analysis of retatrutide's activity at the GLP-1, GIP, and glucagon receptors, including relative potency, selectivity, and why triple agonism produces synergistic metabolic effects that exceed dual-agonist approaches like tirzepatide.
Retatrutide Half-Life and Dosing: Pharmacokinetic Profile Explained
A comprehensive explanation of retatrutide's pharmacokinetic profile, including its approximately 6-day terminal half-life, subcutaneous absorption characteristics, steady-state kinetics, and how these properties compare with semaglutide and tirzepatide.
Retatrutide Development Timeline: From Discovery to Phase 3
A comprehensive chronological timeline of retatrutide's development from its discovery at Eli Lilly through preclinical studies, Phase 1 and Phase 2 clinical trials, landmark publications, and the ongoing Phase 3 TRIUMPH program.
Liver Fat Reduction with Retatrutide: MASLD/NAFLD Implications
An analysis of retatrutide's effects on hepatic steatosis, including clinical trial data on liver fat reduction, the glucagon-mediated mechanism behind these effects, and implications for MASLD/NAFLD treatment.
Regulatory Status of Retatrutide: FDA Pathway and Global Development
Current regulatory status of retatrutide including FDA development pathway, international regulatory landscape, expected approval timeline, and the regulatory requirements for obesity and diabetes indications.
Metabolic Effects of Retatrutide: Glycemic, Lipid, Hepatic, and Cardiovascular Outcomes
An examination of retatrutide's broad metabolic effects beyond weight loss, including glycemic control, lipid improvements, blood pressure reduction, liver fat changes, and implications for metabolic syndrome.
What Is Retatrutide? A Comprehensive Overview of LY3437943
An in-depth introduction to retatrutide (LY3437943), the first-in-class triple GIP/GLP-1/glucagon receptor agonist in development by Eli Lilly for obesity and type 2 diabetes.
Pharmacokinetics of Retatrutide: Absorption, Distribution, Metabolism, and Excretion
A review of retatrutide's pharmacokinetic profile, including its approximately 6-day half-life, subcutaneous bioavailability, albumin binding, and the PK basis for once-weekly dosing.
Pharmacology of Retatrutide: Drug Class, Receptor Binding, and Signal Transduction
A detailed examination of retatrutide's pharmacological profile, including receptor binding affinities, signal transduction pathways, dose-response relationships, and preclinical pharmacology data.